Sichuan Kelun wins bids in national drug procurement, boosting market share prospects

Sichuan Kelun Pharmaceutical and its subsidiaries participated in the 11th round of national centralized drug procurement on October 27-28, 2025, with several products proposed to be successful bids. Key products include Maleate Avatrombopag Tablets (20mg) priced at CNY 49/box and Eltrombopag Olamine Tablets (25mg) at CNY 117/box. Additionally, Compound Sodium Acetate Ringer's Injection is priced at CNY 2.11/bag for 250ml and CNY 3.58/bag for 500ml.

The announcement highlights significant potential for expanded sales and increased market share for the selected products. While specific sales figures for the newly proposed bid products were zero for 2023 and 2024, existing products like Compound Sodium Acetate Ringer's Injection generated CNY 17,726,300 in 2023 and CNY 7,933,100 in 2024 for the 250ml dose.

The company's preliminary success in this national procurement round is expected to positively impact its future operating performance by increasing product sales and strengthening its brand influence. However, the company noted that the finalization of procurement agreements and their impact on future performance remain subject to uncertainty.